Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Federica Ilardi"'
Autor:
Mario Enrico Canonico, Ciro Santoro, Marisa Avvedimento, Giuseppe Giugliano, Giulia Elena Mandoli, Maria Prastaro, Anna Franzone, Raffaele Piccolo, Federica Ilardi, Matteo Cameli, Giovanni Esposito
Publikováno v:
Biomolecules, Vol 12, Iss 2, p 259 (2022)
Acute thrombotic events can unveil occult cancer, as they are its first manifestation in about 20 to 30% of all cases. Malignancy interacts in an intricate way with the hemostatic system, promoting both thrombosis and bleeding. The main pathway invol
Externí odkaz:
https://doaj.org/article/b47ea10db2b4486ca2c23371c0fc6e37
Autor:
Roberta Esposito, Teresa Fedele, Silvia Orefice, Vittoria Cuomo, Maria Prastaro, Mario Enrico Canonico, Federica Ilardi, Francesco De Stefano, Ludovica Fiorillo, Ciro Santoro, Giovanni Esposito
Publikováno v:
Biomolecules, Vol 11, Iss 6, p 785 (2021)
Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that activate the immune system, aiming at enhancing antitumor immunity. ICIs have shown great promise in the treatment of several advanced malignancies. However, therapy with these immuno
Externí odkaz:
https://doaj.org/article/247f123c641e489abf6a33fa24201adf
Autor:
Mario Enrico Canonico, Ciro Santoro, Marisa Avvedimento, Giuseppe Giugliano, Giulia Elena Mandoli, Maria Prastaro, Anna Franzone, Raffaele Piccolo, Federica Ilardi, Matteo Cameli, Giovanni Esposito
Publikováno v:
Biomolecules. 12(2)
Acute thrombotic events can unveil occult cancer, as they are its first manifestation in about 20 to 30% of all cases. Malignancy interacts in an intricate way with the hemostatic system, promoting both thrombosis and bleeding. The main pathway invol
Autor:
Federica Ilardi, Mario Enrico Canonico, Maria Prastaro, Giovanni Esposito, Vittoria Cuomo, Roberta Esposito, Silvia Orefice, Francesco De Stefano, L Fiorillo, Teresa Fedele, Ciro Santoro
Publikováno v:
Biomolecules, Vol 11, Iss 785, p 785 (2021)
Biomolecules
Biomolecules
Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that activate the immune system, aiming at enhancing antitumor immunity. ICIs have shown great promise in the treatment of several advanced malignancies. However, therapy with these immuno